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Summary 
Bordetella pertussis,  the causative agent of whooping cough, adheres to human monocytes/macro- 
phages by means of a bacterial surface-associated protein, filamentous hemagglutinin (FHA) and 
the leukocyte integrin, complement receptor 3 (CR3, ~xmfl2, CDllb/CD18). We show that an 
FHA  Arg-Gly-Asp  site  induces enhanced R  pertussis  binding to  monocytes, and  that  this 
enhancement is blocked by antibodies directed against CR3. Enhancement requires a monocyte 
signal  transduction complex, composed of leukocyte response integrin (a~/33) and integrin- 
associated protein (CD47). This complex is known to upregulate CR3 binding activity.  Thus, 
a bacterial pathogen enhances its own attachment to host cells by coopting a host cell signaling 
pathway. 
A 
tachment of the gram-negative bacterium Bordetella per- 
tuss/s to host cells at or near the respiratory mucosal 
surface is a crucial feature of whooping cough pathogenesis 
in humans. Ciliated respiratory epithelial cells and leukocytes 
are the primary targets for adherence by this organism (1-3). 
This process leads to respiratory tract colonization, systemic 
intoxication, and altered host immune cell function. R per- 
tussis attachment involves a bacterial  surface-associated  and 
secreted  protein, filamentous hemagglutinin (FHA) 1,  and 
host galactose-containing  glycoconjugates (4-7). In addition, 
FHA recognizes a leukocyte B2-integrin, complement recep- 
tor type 3 (CR3,  CDllb/CD18,  ol~2)  (8).  The biologic 
significance of FHA-CR3 recognition and R pertuss/s  binding 
to leukocytes in nature may reflect several possible outcomes, 
including competitive blockade of CR3 by secreted FHA, 
facilitated delivery of bacterial toxins to host leukocytes, and/or 
bacterial intracellular entry, survival, and persistence (9-13). 
A recent study suggests that cross-linking of the fibronectin 
1 Abbreviations used in this paper: FHA, filamentous  hemagglutinin;  lAP, 
integrin-associated  protein; LRI, leukocyte  response integrin; MDM, 
monocyte-derived  macrophages;  PT, pertussis  toxin; RGD, Arg-Gly-Asp. 
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receptor otsfll  on  human peripheral monocytes enhances 
CR3-mediated attachment ofR pertussis via FHA (14). Aug- 
mented fl2-integrin-binding activity can be elicited  by a 
number of other receptor-ligand binding interactions, in- 
cluding CD14 recognition of the LPS-LPS binding protein 
complex (15) and a fl3-integrin-containing receptor signal 
transduction complex (description follows). 
FHA and an intrinsic host ligand for CR3, complement 
fragment iC3b, contain Arg-Gly-Asp (RGD) cell recogni- 
tion sites. These tripeptide motifs often denote binding do- 
mains that are recognized by integrins (16--18). It was ini- 
tially assumed that the FHA and iC3b RGD sites were directly 
recognized by CR3. This assumption was based on the fol- 
lowing observations: (a) an FHA RGD site-directed  muta- 
tion in  the R  /,ertuss/s chromosome significantly reduced 
binding of this bacterium to human macrophages (8); and 
(b) RGD-containing peptides inhibited both iC3b and R per- 
tuss/s binding to monocytes (8, 19). Although FHA and iC3b 
are ligands for CR3,  and their RGD sites are involved in 
binding  interactions  between  these  ligands  and  mono- 
cytes/macrophages, binding studies with purified CR3 have 
demonstrated that the iC3b and FHA RGD sites are not rec- 
ognized by CR3 (20, 21). These results shifted attention to 
a pair of surface-associated protein receptors found on mono- 
cytes/macrophages and neutrophils that do recognize RGD 
sequences, and that appear to regulate integrin activity. 
Leukocyte response  integrin  (LRI)  is  a  heterodimeric 
receptor (ol.~/~3) that is closely associated with a 50-kD pro- 
tein known as integrin-associated protein (IAP) in phago- 
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The LRI ct chain remains poorly characterized;  the/~ chain 
is antigenically closely related to the integrin/~3 chain (CD61). 
LRI recognizes RGD and Lys-Gly-Ala-Gly-Asp-Val sequences 
in a number of basement membrane proteins, and together 
with IAP forms a signal transduction complex (26, 27). Li- 
gation of either of these two proteins on a surface  (cross- 
linking) induces enhanced neutrophil and monocyte chemo- 
taxis, adherence,  phagocytosis, and oxidative burst. Surface- 
bound ligation of LRI or IAP on neutrophils activates  the 
binding activity of CR3 for iC3b, whereas soluble antibodies 
against LRI and IAP inhibit this interaction in a manner similar 
to that of RGD-containing peptides (21). LRI-mediated func- 
tions can be blocked by antibodies that bind to IAP; the in- 
dividual functions of these two proteins have not been dis- 
sociated.  The  pathways that  mediate LRI/IAP  signaling 
remain to be characterized;  however, LRI/IAP-initiated re- 
spiratory burst in neutrophils seems to be independent of 
CD18-dependent signaling (27).  We sought to determine 
whether LRI and IAP might be involved in regulating/i 
pertuss/s adherence to human monocytes  by an FHA-dependent 
mechanism. 
Materials and Methods 
Bacterial Strains and Strain Construction.  B, pertussis BP536 (5) 
is a streptomycin-resistant  derivative  of  BP338 (28), a virulent-phase 
member of the Tohama I lineage. All of the following/g pertuss/s 
strains used in this study are derivatives of BP536. B1>101 contains 
a partial, in-frame deletion of the FHA structural gene, flzaB, 
resulting in truncation of the mature protein product and elimina- 
tion of most FHA-associated adherence functions (5). BlxTOX6 
contains a complete deletion of the pertussis toxin operon (5). 
BP1098 carries a site-directed mutation infl,  aB that effects a sub- 
stitution of Ala for Gly within the RGD site at amino acid posi- 
tions 1097-1099 (8). The double mutant strain BP1098-TOX6 con- 
tains each of the last two described mutations. 
BP200 contains a complete deletion of  JhaB and was constructed 
as follows: a chromosomal PstI-EcoRI fragment of •700  bp, lo- 
cated 253-bp upstream of the~aB open reading frame, was cloned 
from BP536. A chromosomal fragment of "~550 bp, located 140- 
bp downstream of theflzaB  open reading frame, was amplified  from 
BP536 with the PCIL using primers 11170E (5'GGA ATT CGT 
GAA ACT GAC CGA GTG T 3') and 11721H (5' GCG AAG CTT 
CCC GTC ACA AGC GTA TGT 3'). These two fragments were 
ligated in tandem within plasmid pSORTP1, a derivative  of/~ per- 
tuss/s suicide  vector pRTP1 (29) that encodes gentamicin resistance. 
This recombinant phsmid, pSAFHABpl,  was introduced into 
BP536 by conjugation. Merodiploid  exconjugants  with an integrated 
plasmid were sdeeted with gentamicin. Streptomycin  then allowed 
selection for loss of the suicide  plasmid  vector (resolved  merodiploid 
exconjugants). These latter strains were examined for flzaB allelic 
exchange by Southern hybridization and loss of FHA production 
by Western blot analysis.  BP200 was identified as one of theseflzaB 
deletion strains (data not shown). 
Monoclonal Antibodies and FHA Protein.  The following mono- 
clonal antibodies were used in this study (the cognate human 
receptor and source  or reference  are also indicated):  mAb 73, directed 
against a 115-kD monocyte protein with no known function (D. 
Andrews,  unpublished  observations);  KIM118, CDllb  (M. 
Robinson, Celltech  Ltd., Slough, UK); 6.5E, CD18 (M. Robinson, 
Cdltech Ltd.); II34, CD18 (S. D. Wright, The Rockefeller  Univer- 
sity, New York, NY; 30); 7G2, LRI B chain (CD61; F. Lindberg 
and E. Brown, Washington University School of Medicine, St. 
Louis, MO; 22); B6H12 and 2133, IAP (F. Lindberg and E. Brown; 
22, 23); mAb16, cr  integrin chain (S. K. Akiyama, National In- 
stitutes of Health, Bethesda, ME)); mAb13,/Jl integrin chain (S. K. 
Akiyama). 2D3 binds to an lAP epitope distinct from that recog- 
nized by B6H12 and with equal affinity, but causes none of the 
cellular activities that are associated  with LRI/IAP signaling and 
are induced by surfaee-bound B6H12 (22-24). 
Wild-type FHA (RGD) and mutant FHA (RAD) were isolated 
and purified from R pertussis strains BP-TOX6 and BP1098-TOX6, 
respectively,  by use of  previously  published  techniques (31, 32) (some 
material was a gift from A. Kimura and J. Cowell, Lederle-Praxis 
Biologicals Division, American Cyanamid Co., West Henrietta, 
NY), These preparations were then further purified with concen- 
trators (Centricon-3; Amicon Corp., Beverly,  MA). Quantitative 
endotoxin determinations  on the FHA preparations  were performed 
with a limulus amebocyte ELISA assay (Microbiology Reference 
Laboratory, Cincinnati, OH). 
Bacterial Binding to Monocytes.  Monocytes were isolated from 
fresh human peripheral blood obtained from healthy donors by use 
of F'icol-Hypaque  (Pharmach LKB Biotechnology,  Inc., Piscataway, 
NJ) and standard procedures 03). Cells were resuspended  in serum- 
free media consisting of PBS with 3 mM glucose, 150 aM CaCI2, 
500 nM MgClz, 0.3 U  aprotinin/ml,  and 0.05%  human serum 
albumin. Adherence  assays  were performed as previously  described 
(8), with some modifications. Terasaki tissue culture plate wells 
(Nunc, Inc., Napervflle, IL) were precoated with 5 #1 of mAb at 
25 ~tg/ml, or BSA or FHA at variable concentrations overnight 
at 4~  (BSA = 500 ttg/mlunless otherwise stated). After washing, 
wel surfaces  were blocked with serum-free  media at room temper- 
ature for 2 h. After washing, 5/~1 of mononudear cell suspension 
(1.5  x  104 cells) was added to each well, and cells were allowed 
to spread at 37~  for 90 min. Nouadherent cells were removed 
by washing with serum-free media three times, and 5  x  10  s bac- 
teria were incubated in each well at 37~  in serum-free media for 
30 rain. Soluble mAbs were added at 25/~g/ml. After washing 
and staining with Giemsa, the number of  bacteria adherent to 100 
monocytes was determined by light microscopy (i.e,, "attachment 
index"). Each well incubation was performed in triplicate, and each 
experiment was performed on at least three occasions. 
The percentage of monocytes among adherent cells in wells 
was determined by staining for ce-naphthyl butyrate esterase by 
use of standard methods (34). Monocytes comprised 8.4 •  1.0% 
(mean  •  SD) of the total peripheral blood leukocytes from the 
donors used in this study. After Ficoll-Hypaque separation, the 
mononuclear cell fraction was 22.5 •  0.18% (mean •  SD) mono- 
cytes. To assess possible differences  in the percentage of monocytes 
bound by different substrates, adherent eels were stained in wells 
precoated with each of the proteins and antibodies described in 
this study. Determinations under each condition were performed 
in triplicate and expressed as the mean percentage of monocytes 
among total adherent cells. After a 90-min incubation with wel 
surfaces and extensive  washing, monoo/tes comprised  >95% of the 
remaining adherent eels. The monocyte  purity of  the adherent cells 
did not vary in relation to any of the protein or antibody well 
coatings. Adherent bacteria were equally well distributed among 
the adherent monocytes in wells coated with different substrates. 
In the  experiments designed to identify upregulated R  per- 
tuss/s-binding receptor(s) (Table 1), "pretreated" monocytes were 
incubated with mAbs, 25 ~tg/ml, for 15 min at 4~  before place- 
ment in precoated wells; they were then allowed to attach to the 
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Anti-LRl-coated surfaces  FHA-coated  surfaces (5 #g/ml) 
Monocytes  Monocytes 
Antibody  Pretreated*  Posttreated*  Pretreated*  Posttreated* 
None (BSA)  158  •  17  175  _+  4  172  +  13  174  •  16 
73 ((x-MO ag)  141  _+  23  180  _+  10  168  •  28  188  •  20 
7(32 ((X-LILI)  80  _+  18  175  •  6  100  •  29  172  •  17 
B6H12 ((x-IAP)  64  _+  3  170  •  8  99  _+  14  175  +  27 
2D3 ((X-IAP)  179  •  27  173  •  7  165  •  28  183  •  12 
KIM118  ((x-CD11b)  53  •  13  82  •  4  70 _+  9  60  •  8 
IB4 ((X-CD18)  72  •  25  67  •  13  66  +  16  60  •  6 
6.5E ((X-CD18)  56  _+  20  70  _+  4  71  _+  13  74  +  5 
mAb16 ((x-alphas)  143  _+  13  188  _+  20  136  _+  14  171  •  22 
mAb13 ((x-beta  0  149  _+  31  178  _+  6  116  •  6  168  •  19 
Data are expressed a~ mean percentages  of bacterial binding to monocytes cultivated  on uncoated surfaces in the absence of soluble antibody  •  SE; 
"stimulated" refers to monocytes cultivated on surface-bound  substrates  (FHA and  7G2) that lead to enhanced bacterial  binding. 
* Monocytes treated with antibodies  before cultivation in anti-LRl or FHA precoated  wells. 
t Monocytes  treated with antibodies  after  cultivation in anti-LRI or FHA precoated  wells. 
well surface for 90 min at 37~  before bacterial infection. "Post- 
treated" monocytes were allowed to attach to the well surfaces for 
90 rain at 37~  and were then incubated with mAbs, 25/~g/ml, 
for 15 rain at room temperature, before bacterial infection. 
Results 
LRI/IAP Regulates B. pertussis Binding to Monocytes.  Bac- 
terial binding assays were performed on human peripheral 
monocytes in the presence of  monoclonal antibodies directed 
against a variety of monocyte surface molecules. Monocytes 
were exposed to either antibody-coated surfaces or to soluble 
antibodies before incubation with bacteria. In the surface- 
coated format, mobile monocyte surface molecules are ligated 
by antibodies at the substrate-adherent domain of the cell 
and become cross-linked; this reduces their number on the 
ceU apical surface (30, 35). The soluble format allows surface 
molecule blockade. 
In assays of these types, the binding of a wild-type/i per- 
tussis strain, BP536, was significantly reduced to 49-57% of 
control (using BSA) levels by three different surface-bound 
antibodies directed against  either of the subunits  of CR3 
(CDllb/CD18)  (Fig.  1  A).  Binding  of BP536  was  also 
significantly reduced (41-63%) in the presence of the same 
antibodies in soluble form (Fig. 1 B). These results corrobo- 
rated findings from an earlier study implicating CR3 in/i 
pertussis  adherence to human peripheral monocyte-derived 
macrophages (MDM) (8). Interestingly, antibodies 7G2 and 
B6H12, directed against LtLI and IAP, respectively, signifi- 
cantly enhanced BP536 binding to monocytes when used in 
surface-bound format (183  _+  17%, mean _+  SE, and 189  _ 
13%, respectively; Fig.  1 A). On the other hand, these two 
antibodies reduced bacterial binding (63  _+  4%, 52  __.  3%) 
A: Surface-bound mAb 
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73 (ccMO ag)-~.~.~ 
KIM118 (c~CD1  lb) 
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IS4 ((~COl 8) -~,S'AJvA("J/f/'~J-~ 
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Attachment index 
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Figure  1.  Effects ofsurfaee-bound (.4.) and soluble (B) mAhs on R per- 
tussis BP536 binding to human peripheral monocytes.  Attachment index 
corresponds  to the total number of bacteria adherent  to 100 monocytes. 
Shown are mean values and standard errors, based on at least three experi- 
ments,  each performed  in triplicate. 
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inhibition was observed with control mAb 73 or IAP con- 
trol  (nonfunctional)  antibody  2D3  (see Materials  and 
Methods). 
These results with 7G2 and B6H12 are reminiscent of, and 
consistent with, previous observations of upregulated CR3 
binding activity, receptor-mediated phagocytosis, and acti- 
vation of respiratory burst in neutrophils and monocytes  under 
similar  conditions in which LRI and IAP are cross-linked 
at a substrate-cell interface (21, 26, 27). The experiments with 
surface-bound and soluble 7G2,  B6H12, 2D3,  and control 
mAb 73 were repeated with fresh peripheral monocytes from 
two other independent human donors, each examined on three 
separate occasions. The results were essentially identical to 
those presented (data  not shown). 
FHA is Required  for LRI/IAP.mediated lg pertussis Binding 
Enhancement.  A number of/g pertussis proteins have been 
proposed as potential adherence factors. Previous studies have 
most strongly implicated FHA, and less so pertussis toxin 
(PT), in mediating binding to eukaryotic cells and tissues (4, 
5), and, in particular,  to human MDM (8). We studied the 
monocyte-binding activity of/~ pertussis isogenic strains de- 
rived from BP536 that contain partial or total deletions of 
the FHA structural gene (BPl01,  BP200, respectively) or a 
total ddetion of the PT operon (BP-TOX6) with antibodies 
in surface-bound and soluble formats. Using all of the anti- 
bodies previously mentioned  in both formats with BP-TOX6, 
we found that the levels of binding enhancement and inhibi- 
tion were indistinguishable from those observed with BP536 
(Fig. 2, A and B). Conversely, monocyte  binding of the FHA 
mutants BP101 and BP200 was significantly impaired (38  _+ 
5% mean _+ SE, and 41  _+ 9%, respectively, compared with 
BP536)  and was not enhanced by surface-bound 7G2 and 
B6H12 nor inhibited by these antibodies in soluble form. mAbs 
other than 7G2 and B6H12 gave similar results with BP-TOX6 
(data not shown) and BP536 (see Fig. 1); with the FHA mu- 
tant strains,  there were no significant  differences between 
results with any of the mAbs, including the negative control 
antibodies.  These findings suggest that: (a) FHA is a more 
dominant B. pertussis adhesin for monocytes than is PT; (b) 
FHA is required for the LRI/IAP enhancement effect; and 
(c) FHA might directly interact with LRI/IAP. 
Surface-bound FHA  Stimulates LRI/IAP-mediated Binding 
Enhancement.  To determine whether FHA could simulate 
the effects of anti-LRI and anti-lAP antibodies, purified FHA 
protein was used in surface-bound and soluble forms at varying 
densities and concentrations (Fig. 3). In surface-bound form, 
wild-type (RGD-containing) FHA protein produced two 
different effects: at lower densities, e.g., surface coating with 
a 5-/~g/ml solution, B pertussis  monocyte adherence increased 
to 190  •  44% of the levels achieved with BSA; with wells 
coated at higher densities, e.g., a 250-/zg/ml solution, adher- 
ence was reduced to 45  +  16% of BSA levels. The same pro- 
tein used in soluble form caused no adherence enhancement, 
but did cause significant  inhibition of adherence at higher 
concentrations. (If all FHA molecules in 5/zl of 5/~g/mt 
FHA were deposited on the well surface, ligand density would 
be '~5.7  x  103 molecules//zm2.) 
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Figure  2.  Effects of surface-bound (/1) and soluble (B) LILI and IAP 
mAbs on the binding ofB pena~ wild-type, FF-mutant, and FHA-mutant 
strains to human peripheral monocytes. Phenotypes:  Vir +, virulent phase; 
PT-, FHA -, absence of PT and FHA expression, respectively; FHA-def, 
expresses truncated FHA protein; FHA (RAD), expresses FHA protein 
with G---~A  substitution at RGD site. Shown are mean values and stan- 
dard errors, based on at least three experiments, each performed in triplicate. 
Because FHA-mediated enhancement resembled the LRI/ 
lAP effects previously associated with some RGD-containing 
ligands, we examined the activity of a mutant FHA protein 
secreted by BP1098, an isogenic derivative of BP536 that con- 
tains a site-directed chromosomal  mutation resulting in a Gly 
-~ Ala substitution at the RGD site (8). This FHA(RAD) 
in surface-bound form did not enhance B pertuss/s monocyte 
binding at any tested density; however, this protein significantly 
diminished BP536 adherence when used at 250/~g/ml in 
surface-bound and soluble forms. Although endotoxin may 
contribute to monocyte activation, the endotoxin concentra- 
tions in the FHA(RGD) and FHA(RAD) preparations were 
similar:  1.7 and 2.0 ng/ml, respectively. These experiments 
with BSA, FHA(RGD) (at 5 ~g/ml) and FHA(RAD) (at 
5/zg/ml) were repeated with fresh peripheral monocytes  from 
two other independent  donors, each examined on three sepa- 
rate occasions. The results were essentially identical to those 
presented (data  not shown). 
Under nonstimulated  monocyte  conditions, the FHA RAD 
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Figure  3.  Effects of surface-bound (.4) and soluble (B) FHA on BP536 
binding to human peripheral monocytes. Wild-type RGD-containing FHA 
and mutant RAD-containing FHA are compared with BSA. The concen- 
tration of protein solutions  used to precoat  wells is indicated  on the ab- 
scissa. Shown are mean values and standard errors, based on at least three 
experiments,  each performed in triplicate. 
mutant strain, BP1098, was partially deficient in monocyte 
binding (62  _+  10% of BP536 levels; Figs. 2 and 4). Low 
density FHA(RGD) as a surface-bound monocyte ligand was 
able to restore fully the binding of this strain, as did surface- 
bound 7G2 and B6H12. In contrast, these three stimuli of 
enhanced/t pertuss/s adherence did not increase the binding 
of the partial or total FHA deletion mutants (Figs.  2 and 
4).  As a soluble ligand at 50 gg/ml, FHA(RGD) blocked 
surface-bound 7G2-stimulated BP536 binding to the same 
degree as soluble 7G2 or B6H12 (59  +  14% of control anti- 
body, 56  +  5%, and 47  +_  7%, respectively).  In addition, 
soluble 7G2 and soluble B6H12 blocked equally well the en- 
hanced bacterial binding stimulated by surface-bound FHA 
and surface-bound 7G2 when monocytes were pretreated with 
these antibodies (Table 1). Taken together, these findings are 
consistent with the hypothesis that the FHA RGD site in- 
teracts directly with LRI/IAP. We propose that FHA. as a 
surface-bound ligand, cross-links  the LRI/IAP complex by 
means of the RGD site and initiates LRI/IAP-mediated in- 
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Figure 4.  Enhancement ofwild-typeR pertuss/s and FHA(RAD) mu- 
tant strain binding to monocytes by surface-bound low-density FHAOLGD  ). 
For strain phenotypes, see Fig. 2 legend. Shown are mean values and stan- 
dard errors, based on at least th~'e experiments, each performed in triplicate. 
tracellular  signaling in a manner similar to entactin (26). A 
separate  FHA  domain  may  mediate  binding  with  the 
receptor(s) that is upregnlated by this signaling event, as evi- 
denced by the fully restored adherence of BP1098 to mono- 
cytes cultivated on low density FHA(RGD)-coated surfaces. 
We speculate that high density surface-bound FHA reduces, 
rather than enhances, R  pertuss/s binding by capturing the 
binding receptor at the cell-substrate interface. Since we have 
not formally demonstrated  direct binding of FHA to LRI/IAP, 
we cannot rule out at the same time the possibility of an 
indirect mechanism for FHA-induced, LRI/IAP-mediated 
binding enhancement. 
Enhanced B pertussis Monocyte Binding Is Due to Upregulated 
CR3 Activity.  To identify the upregulated binding receptors 
on the monocyte apical surface, soluble antibodies were used 
to block monocyte receptors either before or after monocyte 
incubation in 7G2- and low density FHA(RGD)-coated wells 
(Table 1).  7G2,  B6H12,  and the three antibodies directed 
against CR3 all significantly reduced the LRI and FHA en- 
hancement effects when used to block monocytes  before well 
incubation. However, only the antibodies directed against CR3 
caused significant inhibition of the enhancement effects when 
used to treat monocytes after their attachment to coated wells. 
In separate experiments, the three anti-CR3 antibodies in 
soluble form reduced BP1098 monocyte binding to 42-59% 
of the control antibody levels in uncoated wells. We inter- 
pret these data to indicate that CR3 is the monocyte receptor 
that is upregulated during LRI/IAP signaling and binds 
directly to BL pertussis FHA at a domain other than RGD. 
This leads to enhanced bacterial  attachment to monocytes. 
In all of our experiments, 2D3 was noninhibitory and non- 
functional in soluble and surface-bound forms, as previously 
shown by others (22-24), despite IAP-binding affinity equiva- 
lent to that of B6H12. Since surface-bound 2D3 should cap- 
ture LRI/IAP complexes,  the fact  that/t pertussis bound Figure  5.  Proposed model indicating recognition ofmonocyte  LILI/IAP 
by the R  pertussis FHA RGD site, leading to LRI/IAP cross-linking, in- 
tracelluhr signaling with upregulation of CR3 activity, and enhanced CR3 
recognition of a separate/~ pertussis FHA domain. In this manner,/~ per- 
tussis FHA upregulates its own binding to monocyte CR3. Nonetheless, 
there  is substantial  CR3-B  pertuss/s-binding activity  in the absence of 
surface-bound FHA stimulation.  The CR3-binding domain of FHA is 
currently  undefined. 
equally well to the apical surfaces of monocytes adherent to 
2D3- and control mAb-coated surface suggests that if bac- 
teria do bind directly to LRI/IAP, only a small proportion 
of the total number of monocyte-adherent bacteria are bound 
to this  complex. 
Discussion 
A number of microbial pathogens bind to integrin receptors 
on eukaryotic cell surfaces, either directly or through soluble 
host integrin ligands adsorbed to the microbial surface (36, 
37). The resulting intracellular  signaling events are incom- 
pletely understood, but may be manifested by tyrosine phos- 
phorylation, cytosk~etal rearrangements, and altered cellular 
morphology. The choice ofligand and receptor combinations 
dictate the subsequent  fate of the microorganism. Binding 
affinity may also play a role in these events. For example, high- 
affinity binding of the Yersinia  invasin protein for the ~1 chain 
integrins is crucial for the internalization of this organism 
by nonprofessional phagocytes (36, 38). A  100-fold higher 
dissociation  constant of fibronectin  for the c~sfll integrin, 
compared to invasin, may explain why the latter and not the 
former promotes microbial internalization. The leukocyte f12 
chain integrin, CR3, also serves as a receptor  for a variety 
of microbial  pathogens,  including Legionella pneumophila, 
Rhodococcus equi, Histoplasma capsulatum, and  Leishmania 
(39-42).  The attachment of some of these microorganisms 
to leukocyte CR3 is mediated by deposition of iC3b on the 
microbial surface. In addition to the concurrent role of other 
leukocyte receptors, CR3 receptor activity may be crucial in 
determining the likelihood of phagocytosis, the generation 
of an oxidative burst, and other cellular responses to the ad- 
herent microorganism. 
CR3 and other leukocyte receptors exhibit variable states 
of activation. Stimuli such as phorbol esters, divalent cations 
such as Mn  2+ , integrin modulating factor, and contact with 
surface-bound RGD-containing extracellular matrix ligands 
dramatically  enhance CR3 activity (21, 43-45).  Enhanced 
activity probably reflects various combinations of increased 
surface receptor number, receptor binding affimty, and receptor 
signaling  capabilities.  Manganese  ion enhances/~ peaussis 
binding to monocytes (our unpublished data). Non-B2 chain 
integrins and associated membrane proteins,  such  as ~sB, 
and LRI/IAP, may play important roles in regulating CR3 
activity. Presumably, these forms of receptor activity regula- 
tion are crucial for professional phagocytes as they move be- 
tween bloodstream and tissue sites (27). Microbial pathogens 
may benefit  from  their  own  manipulations  of leukocyte 
receptor  activity modulation./~ pertuss/s FHA may mimic 
RGD-containing extraceUular  matrix proteins by ligating the 
LRI/IAP complex and stimulating CR3 binding activity. 
Our data suggest that/~ pertuss/s FHA may interact with 
the monocyte LRI/IAP complex through the FHA RGD 
site, and that FHA-induced LRI/IAP cross-linking leads to 
upregnlated CR3-mediated binding of/~ pertuss/s to mono- 
cytes. Several types of evidence favor the direct interaction 
of  FHA  with  LRI/IAP:  (a)  soluble  antibodies  against 
LRI/IAP block wild-type/~ pertuss/s binding to monocytes, 
but do not further affect the binding of FHA-deficient/~ 
pertuss/s mutants; (b) pretreatment of monocytes with soluble 
antibodies  against  LRI/IAP  block  sur~ce-bound  FHA- 
mediated enhancement ofR pertuss/s binding to the same de- 
gree that they block surface-bound 7G2-mediated enhance- 
ment; and (c) soluble FHA inhibits surface-bound anti-LRI 
antibody from stimulating enhanced/~/x,  auss/s binding. At 
the same time, we have not ruled out the possibility  that 
the interaction between FHA and LRI/IAP is indirect. Be- 
cause LRI has not been cloned, nor purified in large amounts, 
it is technically difficult to prove direct binding of FHA with 
LRI. Cross-linking reagents  may provide one approach  to 
this problem. 
As with other microbial pathogens, R pertussis adherence 
to mammalian cells is certain to be a complex process. Bac- 
terial adhesin density at the contact points with the eukary- 
otic surface, multiple binding domains within a single adhesin, 
and cooperation among different adhesins are all relevant. The 
density of FHA at  the bacteria-monocyte interface is un- 
known; it is also unclear whether bacterial  surface ligands 
cross-link monocyte receptors in a manner similar to ligand- 
coated plastic surfaces. Secreted FHA may coat other bacteria 
(46), host epithelial  and basal cells, and exposed basement 
membrane.  FHA is also thought to contain a carbohydrate 
recognition domain, as well as other binding domains for 
eukaryotic proteins, besides the RGD site (47-49).  In addi- 
tion, a separate R  pertussis adhesin,  PT, appears to contain 
lectin-like binding domains within subunits  $2 and $3 that 
may mediate and possibly regulate R pertuss/s attachment to 
1230  l~rdetella permssis  Adhesin Interacts  with Monocyte  Signaling Complex leukocytes (50-52).  However, our data demonstrate that a 
FT-deficient strain adheres to human peripheral monocytes 
and responds to LRI/IAP cross-linking as well as the wild- 
type organism. 
Hazenbos et al. (14) provide evidence that R pertussis may 
interact with the fibronectin receptor r  on the monocyte 
surface and that cross-linking of this receptor causes enhanced 
CR3-mediated,  FHA-dependent binding of the bacterium 
to these cells. In our study, when soluble antibodies directed 
against ors chain or/31 chain were incubated with monocytes 
already attached to anti-LRI antibody- or FHA-coated sur- 
faces, there was no inhibition of enhanced R pertuss/s binding 
(Table 1). This finding suggests that activated CR3 may be 
dominant to C1~5~1 as an FHA-binding receptor. However, r 
chain and 131 chain antibodies did appear to inhibit partiaUy 
the FHA-enhanced bacterial binding when they were used 
to pretreat monocytes. It is possible that FHA interacts with 
r  as well as with CR3  and LRI/IAP,  and may also 
cause  some  degree  of  c~s/31 cross-linking  on  monocyte 
surfaces. 
We suggest that a bacterial adherence protein may regu- 
late the binding activity of its own eukaryotic receptor by 
coopting a host signal transduction complex. This concept 
is iUustrated by a model in which R  pertussis FHA may en- 
hance its own binding interactions with human monocytes 
(Fig. 5). If one were to postulate a role for the FHA carbohy- 
drate recognition domain in the initial recognition of mono- 
cyte glycoconjugates, then this model would become strik- 
ingly similar to a muhistep model of leukocyte-endothdial 
cell recognition (53).  The latter process consists of primary 
lectin-mediated transient adhesion, followed by leukocyte ac- 
tivation,  and then activation (CR3)-dependent binding. 
What might be the consequences and relevance in vivo 
of LRI/IAP recognition of FHA and subsequent enhanced 
binding of/~ pertussis to monocyte CR3? Some data suggest 
that R  pertussis enters and survives  within host phagocytes 
to a limited degree (9-13).  Prolonged intracellular survival 
within alveolar macrophages or within cells of the respiratory- 
associated lymphoid tissue might suggest mechanisms for (a) 
R pertussis persistence within the human host; (b) prolonged 
or ddayed clinical manifestations and immune responses; and 
(c) establishment of a R pertuss/s human reservoir, the exis- 
tence  of which  remains  speculative  (54,  55).  LRI/IAP- 
enhanced CR3 binding activity may fadlitate R pertussis in- 
tracellular entry and survival by means of either increased 
CR3 binding avidity or receptor number. In support of this 
notion, we have preliminary evidence that FHA/(RGD) cross- 
linking of LRI/IAP increases the number ofR pertussis that 
enter human peripheral monocytes (our unpublished data). 
LILI/IAP-enhanced CR3 binding ofR pertuss/s may also lead 
to enhanced delivery of R pertussis toxins. Thus, the ultimate 
outcome of the R  pertussis-monocyte  encounter probably 
reflects FI" and adenylate cyclase toxin inhibition of various 
phagocyte intracellular signalling pathways (56,  57).  From 
a general perspective, R  pertussis and FHA may serve as im- 
portant tools for characterizing the functions of LRI/IAP 
and other phagocyte receptors. 
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